Given that CD8+ T cell exhaustion is linked to slower disease progression (26) and positively modulated by teplizumab (9, 10), this signature could serve as a tool for stratifying patients based on their immune phenotypes, thereby optimizing treatment strategies to delay T1D progression. The gene discussed is CD8A; the disease is type 1 diabetes mellitus.